Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
237.10
+0.54 (0.23%)
At close: Aug 28, 2026, 4:00 PM EDT
240.00
+2.90 (1.22%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Alnylam Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 4,804 | 3,714 | 2,248 | 1,828 | 1,037 | 844.29 |
Revenue Growth | 95.14% | 65.19% | 22.97% | 76.23% | 22.88% | 71.31% |
Gross Profit Gross Profit Growth | 3,827 | 3,032 | 1,925 | 1,518 | 868.6 | 704.14 |
Operating Income Operating Income Growth | 999.78 | 501.58 | -176.89 | -282.18 | -785.07 | -708.65 |
Net Income Net Income Growth | 774.71 | 313.75 | -278.16 | -440.24 | -1,131 | -852.82 |
Earnings Per Share EPS Growth | 5.62 | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
AMVUTTRA AMVUTTRA Growth | 3,414 | 2,314 | 970.45 | 557.84 | 93.8 | - |
ONPATTRO ONPATTRO Growth | 109.7 | 172.79 | 252.86 | 354.55 | 557.61 | 474.74 |
GIVLAARI GIVLAARI Growth | 324.83 | 308.49 | 255.87 | 219.25 | 173.14 | 127.82 |
OXLUMO OXLUMO Growth | 205.92 | 191.44 | 167.05 | 109.84 | 69.78 | 59.59 |
Roche - Collaboration Roche - Collaboration Growth | 437.09 | 394.88 | 119.49 | 337.8 | - | - |
Regeneron Pharmaceuticals - Collaboration Regeneron Pharmaceuticals - Collaboration Growth | 81.73 | 113.96 | 302.8 | 100.47 | 87.84 | 113.23 |
Novartis AG - Collaboration Novartis AG - Collaboration Growth | - | - | 79.76 | 86.73 | 43.16 | 49.12 |
Other - Collaboration Other - Collaboration Growth | 3.11 | 44.53 | 8.18 | 21.19 | 3.91 | 18.61 |
Royalty Royalty Growth | 228.22 | 174.02 | 91.79 | 40.63 | 8.18 | 1.2 |
Revenue (Total) Revenue (Total) Growth | 4,804 | 3,714 | 2,248 | 1,828 | 1,037 | 844.29 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,308 | 2,908 | 2,695 | 2,439 | 2,192 | 2,436 |
Total Debt Total Debt Growth | 2,987 | 2,969 | 2,743 | 2,683 | 2,613 | 2,186 |
Net Cash (Debt) Net Cash Growth | 320.66 | -60.31 | -48.92 | -243.24 | -420.15 | 249.87 |
Net Cash Growth | 172.09% | - | - | - | - | -11.29% |
Net Cash Per Share Net Cash Per Share Growth | 2.31 | -0.45 | -0.38 | -1.95 | -3.45 | 2.11 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 911.81 | 524.08 | -8.31 | 104.16 | -541.27 | -641.69 |
Capital Expenditures CapEx Growth | -91.95 | -58.7 | -34.28 | -62.21 | -72.06 | -76.37 |
Free Cash Flow Free Cash Flow Growth | 819.87 | 465.38 | -42.59 | 41.95 | -613.33 | -718.07 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 79.65% | 81.64% | 85.62% | 83.02% | 83.73% | 83.40% |
Operating Margin | 20.81% | 13.51% | -7.87% | -15.43% | -75.68% | -83.94% |
Pretax Margin | 15.95% | 8.70% | -16.79% | -23.71% | -108.63% | -100.93% |
Profit Margin | 16.13% | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% |
FCF Margin | 17.07% | 12.53% | -1.89% | 2.29% | -59.12% | -85.05% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 42.19 | 167.44 | - | - | - | - |
Forward PE | 28.91 | 60.03 | - | - | - | - |
P/FCF Ratio | 38.70 | 112.89 | - | 572.67 | - | - |
PS Ratio | 6.60 | 14.15 | 13.50 | 13.14 | 28.18 | 24.02 |